Maynard Um
-
-
-
-
-
-
-
Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows
-
-
-
-
-
-
-
Structure Therapeutics (GPCR) PT Lowered to $100 at H.C. Wainwright
-
-
-
-
-
-
-
Cantor: 'GPCR has a key near-term update which we think can move the stock higher again'
-
-
-
-
-
-
-
BMO Capital on Structure Therapeutics (GPCR): 'Licensing agreement with Genentech is not the large Pharma partnership that some Structure owners have been anxiously awaiting'
-
-
-
-
-
-
-
Structure Therapeutics (GPCR) PT Raised to $99 at Clear Street
-
-
-
-
-
-
-
Structure Therapeutics' (GPCR) 'Aleniglipron is Well Positioned' - Citizens
-
-
-
-
-
-
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
466,309 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


